The randomized clinical trials about the efficacy of therapy using combinations of denosumab and immune checkpoint inhibitors (ICIs) targeting CTLA4, programmed cell death protein 1 (PD1), or programmed cell death 1 ligand 1 (PDL1) have not been prospectively unfolded in tumor bone metastasis patients. Here, CD274 is linked to neoplasm.